Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) was the target of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 3,170,000 shares, an increase of 16.1% from the April 15th total of 2,730,000 shares. Based on an average daily volume of 483,100 shares, the […]
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) – Investment analysts at HC Wainwright cut their Q2 2023 EPS estimates for shares of Adicet Bio in a research report issued on Wednesday, May 10th. HC Wainwright analyst E. White now anticipates that the company will earn ($0.73) per share for the quarter, down from their prior […]
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) – Analysts at Wedbush lifted their FY2023 earnings estimates for shares of Adicet Bio in a report released on Wednesday, May 10th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($3.38) for the year, up from their prior forecast of ($3.44). […]
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive... | June 16, 2023
First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales increased 37% to $2.49 billion versus first quarter 2022First... | May 4, 2023